Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has signed a written informed consent prior to the first study intervention~* Is at least 18 and \<85 years of age~* Has one or more diabetic foot ulcers on the target limb, with only one marked for the study (target ulcer). It must have the following characteristics:Plantar; Grade 2 per Curative Health Services Classification; Non-infected; Neuropathic; Non-malignant; At least 1.0-25cm\^2 post-debridement; Present for at least 6 weeks~* Has Type I or II Diabetes Mellitus with an HBA1c between 6-10%~* Has a maximum fasting blood glucose level of 13.8 mmol/L~* An ankle-brachial systolic pressure index between 0.7 and 1.3~* If female and of childbearing potential has a negative serum pregnancy test and is neither breastfeeding or intending to become pregnant during the study~* Able and willing to attend the scheduled visits and comply with study procedures.~Exclusion Criteria:~* Known or suspected disease of the immune system~* Active or untreated malignancy or active, uncontrolled connective tissue disease~* Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before enrollment~* Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement~* Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to enrollment~* Active febrile illness~* AST, ALT, ALP \>3x the normal upper limit~* Serum Creatinine \>2x the normal upper limit~* Osteomyelitis~* Active Charcot~* Use of any topical treatments other than SOC (standard of care)at the time of enrollment~* Enrollment in any investigational clinical trial within 30 days of the screening visit~* Known or suspected hypersensitivity to any study product components~* Recent or current history of alcohol or drug abuse~* Any condition, which in the opinion of the Investigator, would interfere with the evaluation of the study product or poses a health risk to the subject~* All site personnel directly affiliated with this study and their immediate families

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).